Results 171 to 180 of about 1,013,409 (346)

Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021

Arthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is a rare autoimmune disease characterized by tissue fibrosis, vasculopathy, and immune dysregulation. Our objectives were to quantify the overall and site‐specific cancer risks in patients with SSc compared to the general population, examine temporal trends in cancer incidence following SSc diagnosis, and explore ...
Jihyun Na, Su Jin Choi, Sojeong Park, Minae Park, Doo‐Ho Lim   +4 more
wiley   +1 more source

Letter on “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

Annals of Clinical and Translational Neurology, EarlyView.
Raveena Vij, Alexander J. Jonokuchi, Ilya Kister   +2 more
wiley   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Journal of Pharmaceutical Sciences [PDF]

, 2006
H Y Kuan, David E. Smith
openalex   +1 more source

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Chemistry and pharmaceutical sciences always together

Brazilian Journal of Pharmaceutical Sciences, 2010
Elizabeth Igne Ferreira
doaj   +1 more source

The Individual Medication Counseling to the Outpatient with Diabetes Mellitus by the Stuff of Faculty of Pharmaceutical Sciences and Clinical Training for the Students.

, 2000
Hiroaki Araki, Hiromu Kawasaki, Michihiro Izushi, Koujiro Futagami, Kenichi Shikata, Jun ichi Wada, Hikaru Sugimoto, Masahiko Kushiro, Hirofumi Makino, Yutaka Gomita   +9 more
openalex   +2 more sources

Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health Administration

Arthritis Care &Research, Accepted Article.
Objective Though used frequently to treat flare, risk of chronic opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed chronic opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Headaches in a university setting: the case of students at the Faculty of Medicine and Pharmaceutical Sciences, University of Douala. [PDF]

J Headache Pain
Magnerou AM, Massi Gams D, Mbuanguere Mouiche A, Bila Gueumekane EL, Marieya Tuikue A, Sini V, Doumbe JN, Kuate-Tegueu C, Njankouo Mapoure Y.   +8 more
europepmc   +1 more source

Fungal Genetics, Genomics, and Secondary Metabolites in Pharmaceutical Sciences [PDF]

, 2007
Mathias Misiek, Dirk Hoffmeister
openalex   +1 more source